Clarity AI and GIST Impact Team Up to Launch Market-Leading Biodiversity Assessment and Reporting Capabilities
9.5.2023 10:00:00 EEST | Business Wire | Press release
Leading sustainability technology platform, Clarity AI, and leading impact data and intelligence provider, GIST Impact, have announced their latest partnership in the development of a biodiversity impact assessment product. This innovative solution comes at a time when biodiversity-themed funds have gained nearly $1 billion in assets this year, indicating the growing recognition of the financial industry's role in mitigating biodiversity risks.
By utilizing Clarity AI's comprehensive product ecosystem and market-leading coverage along with GIST Impact's 15 years of experience and expertise in biodiversity and impact metrics, the partnership will provide a market-leading solution that helps clients identify and size their exposure to companies that have a negative impact on biodiversity. This will ultimately facilitate informed investment decisions and company engagement practices.
“The imperative for investors to account for biodiversity impacts in their decision-making has never been greater. We’re excited to partner with Clarity AI, combining their deep technology expertise with our industry-leading biodiversity impact methodology and data. Together we’re providing access to credible biodiversity data that is company-specific, geographically accurate, and provides the most holistic coverage of biodiversity impact drivers. This data is critical for effective risk management, and to support action to curb further nature loss,” said Pavan Sukhdev, Founder and CEO, GIST Impact.
This partnership will also ensure that clients are well-equipped for the latest regulatory developments, such as the Sustainable Finance Disclosure Regulation (SFDR) and the Taskforce on Nature-related Financial Disclosures (TNFD).
"Partnering with GIST Impact is a significant step for Clarity AI as it enables us to leverage their extensive experience, knowledge, platforms and data on biodiversity impact assessments. Through this partnership, we can provide our clients with the most accurate and up-to-date information on biodiversity risks, allowing them to make informed investment decisions and engage with companies in a meaningful way," said Angel Agudo, VP of Product and Board Director at Clarity AI.
About Clarity AI
Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, organizations, and consumers. Clarity AI’s capabilities are an essential tool for end-to-end sustainability analysis related to investing, corporate research, benchmarking, consumer ecommerce, and regulatory reporting. As of January 2023, Clarity AI’s platform analyzes more than 70,000 companies, 360,000 funds, 198 countries, and 199 local governments, which represents the broadest data coverage in the market with up to 13 times more than other leading players. One way Clarity AI delivers on its mission to bring societal impact to markets is by ensuring its capabilities are delivered directly into clients' workflows through integrations with partners like BlackRock - Aladdin, Refinitiv an LSEG business, BNP Manaos, Allfunds, and Simcorp. Additionally, Clarity AI's sustainability insights reach more than 150 million consumers across more than 400,000 merchants on the Klarna platform. Clarity AI has offices in North America, Europe, and the Middle East, and its client network manages tens of trillions in assets and includes companies like Invesco, Nordea, BlackRock, Santander, Wellington, and BNP Paribas.
About GIST Impact
GIST Impact is a leading impact data and analytics provider that has been measuring and quantifying corporate impacts for more than 15 years. GIST Impact’s historic and deep expertise in the economics of ecosystems and biodiversity (TEEB) enriches its clients' knowledge of their impacts and dependencies on nature. With a team of 100+ scientists, engineers, data scientists and ecological and environmental economists, GIST Impact codifies this experience within its market-leading impact platforms and datasets, covering 12,800+ companies with geographically precise, time-series data. GIST Impact works with pioneering companies across all sectors and with investors representing over $8 trillion in assets under management. GIST Impact also partners with some of the world's largest ESG data providers, business networks, and fintech platforms to enable impact measurement across global markets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230504005114/en/
Contact information
Clarity AI Media
Edelman
clarityAI@edelmansmithfield.com
GIST Impact Media
Alexandra Downs
alexandra@gistimpact.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom